Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
August 09, 2022 08:00 ET
|
Agenus Inc.
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer...
Agenus to Participate at BTIG Biotechnology Conference
August 02, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
August 01, 2022 08:30 ET
|
Agenus Inc.
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical data support best-in-class potential of AGEN1571 LEXINGTON,...
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
July 27, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
Agenus to Participate at William Blair’s Biotech Focus Conference
June 30, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
June 29, 2022 07:00 ET
|
Agenus Inc.
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapyResponses to botensilimab/balstilimab were durable, with 80%...
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
June 21, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions
June 10, 2022 08:00 ET
|
Agenus Inc.
First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and aboveThird AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver...
Agenus Advances Portfolio with 6 Clinical Collaborations
May 31, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to...
Agenus Announces Virtual Annual Shareholders Meeting
May 25, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...